<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35715944</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology.</ArticleTitle><Pagination><StartPage>e13100</StartPage><MedlinePgn>e13100</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13100</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/bpa.13100</ELocationID><Abstract><AbstractText>This study aimed to assess and compare the burden of transactive response DNA-binding protein of 43&#xa0;kDa (TDP-43) pathology and clinical features of amyotrophic lateral sclerosis (ALS) in three age groups. All cases were from the Mayo Clinic brain bank for neurodegenerative disorders and most were followed longitudinally in the ALS Clinic. Cases with moderate-to-severe Alzheimer's disease neuropathological change were excluded. The 55 cases included in the study were divided into three groups by age at death: 75&#x2009;years or older (old-ALS, n&#xa0;=&#xa0;8), 64-74&#x2009;years (middle-ALS, n&#xa0;=&#xa0;23), and 63&#x2009;years or younger (young-ALS, n&#xa0;=&#xa0;24). Clinical features, including disease duration, initial symptoms, and ALS Cognitive Behavior Score (ALS-CBS), were summarized. Sections of paraffin-embedded tissue from the motor cortex, basal forebrain, medial temporal lobe, and middle frontal gyrus were processed for phospho-TDP-43 immunohistochemistry. The burden of TDP-43 pathology was analyzed using digital image analysis. The TDP-43 burden in the limbic system (i.e., amygdala, dentate gyrus and CA1 sector of the hippocampus, subiculum, and entorhinal cortex) was greater in old-ALS than in young-ALS and middle-ALS. TDP-43 burden in the middle frontal gyrus was sparse and did not differ between the three groups. The average of ALS-CBS was not different between the three groups. The present study shows that the amygdala and hippocampus are vulnerable to TDP-43 pathology in older patients with ALS. We discuss the evidence for and against this pathology being related to concurrent limbic-predominant, age-related TDP-43 encephalopathy neuropathologic change.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Brain Pathology published by John Wiley &amp; Sons Ltd on behalf of International Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Murakami</LastName><ForeName>Aya</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4088-5005</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koga</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8868-9700</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sekiya</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boylan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Josephs</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0003-2930-8634</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS120992</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062077</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">LATE</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">limbic system</Keyword><Keyword MajorTopicYN="N">neuropathology</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35715944</ArticleId><ArticleId IdType="pmc">PMC9616086</ArticleId><ArticleId IdType="doi">10.1111/bpa.13100</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP&#x2010;43 is a component of ubiquitin&#x2010;positive tau&#x2010;negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishima T, Koga S, Lin WL, Kasanuki K, Castanedes&#x2010;Casey M, Wszolek ZK, et al. Perry syndrome: a distinctive type of TDP&#x2010;43 proteinopathy. J Neuropathol Exp Neurol. 2017;76(8):676&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901076</ArticleId><ArticleId IdType="pubmed">28789478</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic&#x2010;predominant age&#x2010;related TDP&#x2010;43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65(4):586&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116120</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Tan CF, Onodera O, Toyoshima Y, Yamada M, Morita T, et al. Sporadic amyotrophic lateral sclerosis: two pathological patterns shown by analysis of distribution of TDP&#x2010;43&#x2010;immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol. 2008;116(2):169&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">18481073</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP&#x2010;43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">31501588</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM. Multiple pathologies are common and related to dementia in the oldest&#x2010;old: the 90+ study. Neurology. 2015;85(6):535&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4540246</ArticleId><ArticleId IdType="pubmed">26180144</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Libard S. Mixed brain pathology is the most common cause of cognitive impairment in the elderly. J Alzheimers Dis. 2020;78(1):453&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">33016922</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese KE, Colloby SJ, Thomas AJ, Al&#x2010;Sarraj S, Ansorge O, Neal J, et al. Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. Alzheimers Dement. 2021;17(7):1121&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">33663011</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM, et al. TAR DNA&#x2010;binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. Ann Neurol. 2015;78(5):697&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623932</ArticleId><ArticleId IdType="pubmed">26224156</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Kouri N, Walton RL, Ebbert MTW, Josephs KA, Litvan I, et al. Corticobasal degeneration with TDP&#x2010;43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathol. 2018;136(3):389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309287</ArticleId><ArticleId IdType="pubmed">29926172</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchino A, Takao M, Hatsuta H, Sumikura H, Nakano Y, Nogami A, et al. Incidence and extent of TDP&#x2010;43 accumulation in aging human brain. Acta Neuropathol Commun. 2015;3:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4473839</ArticleId><ArticleId IdType="pubmed">26091809</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador&#x2010;Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP&#x2010;43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007;61(5):435&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Buciuc M, Whitwell JL, Baker MC, Rademakers R, Dickson DW, Josephs KA. Old age genetically confirmed frontotemporal lobar degeneration with TDP&#x2010;43 has limbic predominant TDP&#x2010;43 deposition. Neuropathol Appl Neurobiol. 2021;47:1050&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8576062</ArticleId><ArticleId IdType="pubmed">33969528</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K, Levine T, Lomen&#x2010;Hoerth C, Lyon M, Maginnis K, Callas P, et al. Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17(1&#x2013;2):119&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">26462131</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond J, Oskarsson B, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) registry, 2010&#x2010;2015. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5&#x2013;6):413&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946020</ArticleId><ArticleId IdType="pubmed">31131638</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging&#x2010;Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer&#x2010;related changes. Acta Neuropathol. 1991;82(4):239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of a beta&#x2010;deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Liesinger AM, Graff&#x2010;Radford NR, Duara R, Carter RE, Hanna Al&#x2010;Shaikh FS, Koga S, et al. Sex and age interact to determine clinicopathologic differences in Alzheimer's disease. Acta Neuropathol. 2018;136(6):873&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280837</ArticleId><ArticleId IdType="pubmed">30219939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, Shaw G, Sharma VP, Yang C, McGowan E, Dickson DW. Actin&#x2010;binding proteins coronin&#x2010;1a and IBA&#x2010;1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem. 2007;55(7):687&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">17341475</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Arumanayagam AS, Powell SZ, Rivera AL, Abner EL, Roman GC, et al. Patterns of amygdala region pathology in LATE&#x2010;NC: subtypes that differ with regard to TDP&#x2010;43 histopathology, genetic risk factors, and comorbid pathologies. Acta Neuropathol. 2022;143(5):531&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038848</ArticleId><ArticleId IdType="pubmed">35366087</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging&#x2010;Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwinn&#x2010;Hardy K, Mehta ND, Farrer M, Maraganore D, Muenter M, Yen SH, et al. Distinctive neuropathology revealed by alpha&#x2010;synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol. 2000;99(6):663&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867800</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki N, Murray ME, Ogaki K, Fujioka S, Rutherford NJ, Rademakers R, et al. Hippocampal sclerosis in Lewy body disease is a TDP&#x2010;43 proteinopathy similar to FTLD&#x2010;TDP type A. Acta Neuropathol. 2015;129(1):53&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282950</ArticleId><ArticleId IdType="pubmed">25367383</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, et al. Staging of argyrophilic grains: an age&#x2010;associated tauopathy. J Neuropathol Exp Neurol. 2004;63(9):911&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15453090</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasanuki K, Heckman MG, Diehl NN, Murray ME, Koga S, Soto A, et al. Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease. Mov Disord. 2017;32(11):1584&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5915345</ArticleId><ArticleId IdType="pubmed">28949048</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley SC, York MK, Moore DH, Strutt AM, Murphy J, Schulz PE, et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS cognitive behavioral screen (ALS&#x2010;CBS). Amyotroph Lateral Scler. 2010;11(3):303&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">20433413</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda Y. Investigation of the freely available easy&#x2010;to&#x2010;use software &#x2018;EZR&#x2019; for medical statistics. Bone Marrow Transplant. 2013;48(3):452&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590441</ArticleId><ArticleId IdType="pubmed">23208313</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss&#x2010;Coray T. Ageing, neurodegeneration and brain rejuvenation. Nature. 2016;539(7628):180&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5172605</ArticleId><ArticleId IdType="pubmed">27830812</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike Y, Sugai A, Hara N, Ito J, Yokoseki A, Ishihara T, et al. Age&#x2010;related demethylation of the TDP&#x2010;43 autoregulatory region in the human motor cortex. Commun Biol. 2021;4(1):1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8455575</ArticleId><ArticleId IdType="pubmed">34548609</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff&#x2010;Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Mackenzie I, Frosch MP, Bigio EH, Neumann M, Arai T, et al. LATE to the PART&#x2010;y. Brain. 2019;142(9):e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6736234</ArticleId><ArticleId IdType="pubmed">31359030</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Porta S, Garrett FG, Zhang P, Xie SX, Suh E, et al. Limbic&#x2010;predominant age&#x2010;related TDP&#x2010;43 encephalopathy differs from frontotemporal lobar degeneration. Brain. 2020;143(9):2844&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526723</ArticleId><ArticleId IdType="pubmed">32830216</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, et al. Updated TDP&#x2010;43 in Alzheimer's disease staging scheme. Acta Neuropathol. 2016;131(4):571&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5946692</ArticleId><ArticleId IdType="pubmed">26810071</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Lin WL, Walton RL, Ross OA, Dickson DW. TDP&#x2010;43 pathology in multiple system atrophy: colocalization of TDP&#x2010;43 and &#x3b1;&#x2010;synuclein in glial cytoplasmic inclusions. Neuropathol Appl Neurobiol. 2018;44(7):707&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6191374</ArticleId><ArticleId IdType="pubmed">29660838</ArticleId></ArticleIdList></Reference><Reference><Citation>Meneses A, Koga S, O'Leary J, Dickson DW, Bu G, Zhao N. TDP&#x2010;43 pathology in Alzheimer's disease. Mol Neurodegener. 2021;16(1):84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691026</ArticleId><ArticleId IdType="pubmed">34930382</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom&#xe9; SO, Gomes LA, Li X, Vandenberghe R, Tousseyn T, Thal DR. TDP&#x2010;43 interacts with pathological &#x3c4; protein in Alzheimer's disease. Acta Neuropathol. 2021;141(5):795&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33797585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Dickson DW. Ultrastructural localization of TDP&#x2010;43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol. 2008;116(2):205&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706695</ArticleId><ArticleId IdType="pubmed">18607609</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Perkerson RB, et al. Pathological, imaging and genetic characteristics support the existence of distinct TDP&#x2010;43 types in non&#x2010;FTLD brains. Acta Neuropathol. 2019;137(2):227&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358471</ArticleId><ArticleId IdType="pubmed">30604226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Wu F, Xu W, Shi J, Hu W, Jin N, et al. TDP&#x2010;43 suppresses tau expression via promoting its mRNA instability. Nucleic Acids Res. 2017;45(10):6177&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5449590</ArticleId><ArticleId IdType="pubmed">28335005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Chen F, Iqbal K, Gong CX, Wang X, Liu F. Transactive response DNA&#x2010;binding protein 43 (TDP&#x2010;43) regulates alternative splicing of tau exon 10: implications for the pathogenesis of tauopathies. J Biol Chem. 2017;292(25):10600&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5481566</ArticleId><ArticleId IdType="pubmed">28487370</ArticleId></ArticleIdList></Reference><Reference><Citation>Moszczynski AJ, Harvey M, Fulcher N, de Oliveira C, McCunn P, Donison N, et al. Synergistic toxicity in an in vivo model of neurodegeneration through the co&#x2010;expression of human TDP&#x2010;43M337V and tauT175D protein. Acta Neuropathol Commun. 2019;7(1):170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6839082</ArticleId><ArticleId IdType="pubmed">31703746</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther. 2014;6(9):82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239398</ArticleId><ArticleId IdType="pubmed">25419243</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>